# Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2

> **NCT04604470** · — · UNKNOWN · sponsor: **Maastricht University** · enrollment: 126 (estimated)

## Conditions studied

- NSCLC Stage IV
- Lung Cancer
- Non Small Cell Lung Cancer
- Metastatic Cancer

## Interventions

- **OTHER:** Decision tool

## Key facts

- **NCT ID:** NCT04604470
- **Lead sponsor:** Maastricht University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-20
- **Primary completion:** 2023-10-01
- **Final completion:** 2023-12
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2020-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04604470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04604470, "Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04604470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*